Literature DB >> 10362314

Neurokinin-3 receptor distribution in rat and human brain: an immunohistochemical study.

D Mileusnic1, J M Lee, D J Magnuson, M J Hejna, J E Krause, J B Lorens, S A Lorens.   

Abstract

Autoradiographic and immunohistochemical studies have shown that the neurokinin-3 receptor is widely distributed in the rodent CNS. Expression of the neurokinin-3 receptor in human brain, however, has been debated. These conflicting findings, as well as the poor resolution of autoradiographic images, prompted us to develop a polyclonal antibody against an oligopeptide derived from the carboxy-terminus consensus sequence of both the rat and human neurokinin-3 receptor ([C]ASTTSSFISSPYTSVDEYS, amino acids 434-452 of the rat neurokinin-3 receptor). Western blot analysis of both human and rat brain tissue revealed a major band in the molecular weight range 65,000-67,000, the proposed molecular weight of the neurokinin-3 receptor based on its amino acid sequence and presumed glycosylation state. The distribution of selective high affinity neurokinin-3 receptor agonist [3H]senktide binding and neurokinin-3 receptor immunoreactivity were virtually identical in the brains of male Fischer 344 rats. The highest concentrations of neurokinin-3 receptors were observed in cortical layers IV-V; the basolateral amygdaloid nucleus; the hypothalamic paraventricular, perifornical and supraoptic nuclei; the zona incerta; and the entopeduncular and interpeduncular nuclei. [3H]senktide binding and neurokinin-3 receptor immunoreactivity were compared in homologous cortical areas of the human and rat brain. In contrast to the rat, autoradiographic analysis of normal control human brains (35-75 years) revealed a distinct and predominant superficial cortical labeling in the glia limitans and the cortical layer I. However, neurokinin-3 receptor immunoreactivity could be found not only in the superficial cortical layers, but also on pyramidal neurons and astrocytes in the neuropil and white matter. These findings suggest species differences in both the cellular and anatomical distribution of the neurokinin-3 receptor.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10362314     DOI: 10.1016/s0306-4522(98)00349-2

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  26 in total

1.  Characterization of RO4583298 as a novel potent, dual antagonist with in vivo activity at tachykinin NK₁ and NK₃ receptors.

Authors:  P Malherbe; F Knoflach; M C Hernandez; T Hoffmann; P Schnider; R H Porter; J G Wettstein; T M Ballard; W Spooren; L Steward
Journal:  Br J Pharmacol       Date:  2011-02       Impact factor: 8.739

2.  Substance P enhances excitatory synaptic transmission on spinally projecting neurons in the rostral ventromedial medulla after inflammatory injury.

Authors:  Liang Zhang; Donna L Hammond
Journal:  J Neurophysiol       Date:  2009-06-03       Impact factor: 2.714

3.  Trafficking of tachykinin neurokinin 3 receptor to nuclei of neurons in the paraventricular nucleus of the hypothalamus following osmotic challenge.

Authors:  D Jensen; Z Zhang; F W Flynn
Journal:  Neuroscience       Date:  2008-05-24       Impact factor: 3.590

4.  Adaptive plasticity in tachykinin and tachykinin receptor expression after focal cerebral ischemia is differentially linked to gabaergic and glutamatergic cerebrocortical circuits and cerebrovenular endothelium.

Authors:  R Stumm; C Culmsee; M K Schafer; J Krieglstein; E Weihe
Journal:  J Neurosci       Date:  2001-02-01       Impact factor: 6.167

5.  Distribution and pharmacological characterization of primate NK-1 and NK-3 tachykinin receptors in the central nervous system of the rhesus monkey.

Authors:  Masatoshi Nagano; Fumihito Saitow; Eisuke Haneda; Shiro Konishi; Motoharu Hayashi; Hidenori Suzuki
Journal:  Br J Pharmacol       Date:  2006-02       Impact factor: 8.739

6.  Arcuate kisspeptin/neurokinin B/dynorphin (KNDy) neurons mediate the estrogen suppression of gonadotropin secretion and body weight.

Authors:  Melinda A Mittelman-Smith; Hemalini Williams; Sally J Krajewski-Hall; Josephine Lai; Philippe Ciofi; Nathaniel T McMullen; Naomi E Rance
Journal:  Endocrinology       Date:  2012-04-16       Impact factor: 4.736

7.  Pharmacokinetics and central nervous system effects of the novel dual NK1 /NK3 receptor antagonist GSK1144814 in alcohol-intoxicated volunteers.

Authors:  Erik T te Beek; Justin L Hay; Jonathan N Bullman; Clare Burgess; Kimberly J Nahon; Erica S Klaassen; Frank A Gray; Joop M A van Gerven
Journal:  Br J Clin Pharmacol       Date:  2013-05       Impact factor: 4.335

8.  Substance P drives endocannabinoid-mediated disinhibition in a midbrain descending analgesic pathway.

Authors:  Geoffrey M Drew; Benjamin K Lau; Christopher W Vaughan
Journal:  J Neurosci       Date:  2009-06-03       Impact factor: 6.167

9.  The tachykinin peptide neurokinin B binds copper forming an unusual [CuII(NKB)2] complex and inhibits copper uptake into 1321N1 astrocytoma cells.

Authors:  Debora Russino; Elle McDonald; Leila Hejazi; Graeme R Hanson; Christopher E Jones
Journal:  ACS Chem Neurosci       Date:  2013-08-07       Impact factor: 4.418

10.  The neurokinin-3 (NK3) and the neurokinin-1 (NK1) receptors are differentially targeted to mesocortical and mesolimbic projection neurons and to neuronal nuclei in the rat ventral tegmental area.

Authors:  Andrée Lessard; Martin Savard; Fernand Gobeil; Joseph P Pierce; Virginia M Pickel
Journal:  Synapse       Date:  2009-06       Impact factor: 2.562

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.